North Carolina Patent of the Month – April 2023
Post-prandial hypoglycemia (PPH) is a common side effect of gastric surgeries including gastric bypass surgery and Nissen fundoplication. Patients who experience PPH may suffer from early or late dumping, which can cause a range of symptoms such as vasomotor symptoms, abdominal pain, diarrhea, dizziness, and weakness. While nutritional modifications and pharmacological therapy can help manage these symptoms, there is still a need for an effective and convenient alternative PPH therapy that does not require strict patient compliance.
Avolynt, Inc. has developed a novel approach to treating PPH associated with gastric surgery by inhibiting the absorption of carbohydrates at the small intestine. This is achieved by blocking the activity of the sodium-dependent glucose transporter (SGLT), which is responsible for the absorption of glucose in the small intestine and the reabsorption of glucose in the renal proximal tubule.
Avolynt’s compound, Mizagliflozin, is a potent inhibitor of SGLT1, with a high degree of selectivity for this subtype of SGLT, which is primarily expressed in the small intestine. It has been shown to have low systemic exposure, acting locally in the gut, and is well-tolerated. Avolynt’s research suggests that Mizagliflozin could be a promising treatment option for PPH associated with gastric surgery, as it can prevent an increase in blood sugar levels, thereby reducing or preventing the occurrence of PPH.
While nutritional modifications and pharmacological therapy are still useful for managing PPH symptoms, Avolynt’s approach provides an alternative therapy that could be more convenient for patients who struggle with strict dietary modifications. Further research is needed to confirm the efficacy of Mizagliflozin in treating PPH associated with gastric surgery, but early results are promising. Avolynt’s innovative approach to treating PPH has the potential to improve the quality of life for patients who suffer from this condition, and represents a significant advancement in the field of gastric surgery.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.